Head to Head Contrast: TruBridge (NASDAQ:TBRG) & Enovis (NYSE:ENOV)

TruBridge (NASDAQ:TBRG) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares TruBridge and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TruBridge	0.92%	18.75%	8.32%
Enovis	-49.92%	10.32%	4.57%

Institutional & Insider Ownership

88.6% of TruBridge shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 10.7% of TruBridge shares are held by insiders. Comparatively, 2.9% of Enovis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TruBridge and Enovis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TruBridge	$346.84 million	1.13	$4.21 million	$0.20	130.90
Enovis	$2.25 billion	0.56	-$1.18 billion	($19.88)	-1.10

TruBridge has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than TruBridge, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TruBridge has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for TruBridge and Enovis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TruBridge	0	8	0	0	2.00
Enovis	1	1	7	0	2.67

TruBridge currently has a consensus price target of $23.95, indicating a potential downside of 8.52%. Enovis has a consensus price target of $44.50, indicating a potential upside of 103.01%. Given Enovis’ stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than TruBridge.

Summary

TruBridge beats Enovis on 8 of the 14 factors compared between the two stocks.

About TruBridge

TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in three segments: Revenue Cycle Management (RCM), Electronic Health Record (HER), and Patient Engagement. It focuses on providing RCM solutions for care settings, regardless of primary healthcare information solutions provider along with business management, consulting, managed IT services, and analytics and business intelligence. The company provides acute care solutions and related services for community hospitals, and physician clinics; and patient engagement and empowerment technology solutions to improve patient outcomes and engagement strategies with care providers. In addition, it offers patient liability estimates eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management; and offers RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services. Further, it offers consulting and business management services; managed IT services; encoder solutions; patient management; financial accounting; clinical; patient care; and enterprise applications. Additionally, it offers TruBridge HER platform, including total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, and public cloud infrastructure services; post-acute care software systems, and support and maintenance services; and InstantPHR, an interactive portal and CHBase which funnels data from multiple sources into one platform. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.